Home LiteratureArticle Details
PMID: 24177718 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

EXPANDS: expanding ploidy and allele frequency on nested subpopulations.

Bioinformatics (Oxford, England) ·Vol. 30 ·No. 1 ·2014-01-01 ·Pages 50-60

Andor N, Harness JV, Müller S, Mewes HW, Petritsch C

Abstract

Several cancer types consist of multiple genetically and phenotypically distinct subpopulations. The underlying mechanism for this intra-tumoral heterogeneity can be explained by the clonal evolution model, whereby growth advantageous mutations cause the expansion of cancer cell subclones. The recurrent phenotype of many cancers may be a consequence of these coexisting subpopulations responding unequally to therapies. Methods to computationally infer tumor evolution and subpopulation diversity are emerging and they hold the promise to improve the understanding of genetic and molecular determinants of recurrence. To address cellular subpopulation dynamics within human tumors, we developed a bioinformatic method, EXPANDS. It estimates the proportion of cells harboring specific mutations in a tumor. By modeling cellular frequencies as probability distributions, EXPANDS predicts mutations that accumulate in a cell before its clonal expansion. We assessed the performance of EXPANDS on one whole genome sequenced breast cancer and performed SP analyses on 118 glioblastoma multiforme samples obtained from TCGA. Our results inform about the extent of subclonal diversity in primary glioblastoma, subpopulation dynamics during recurrence and provide a set of candidate genes mutated in the most well-adapted subpopulations. In summary, EXPANDS predicts tumor purity and subclonal composition from sequencing data. EXPANDS is available for download at http://code.google.com/p/expands (matlab version--used in this manuscript) and http://cran.r-project.org/web/packages/expands (R version).

MeSH Terms
Gene Frequency Glioblastoma/genetics,pathology Humans Mutation Neoplasms/genetics Ploidies Probability Recurrence
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Andor Noemi
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA, Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany, Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94158, USA, Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA, Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA, Chair of Genome Oriented Bioinformatics, Center of Life and Food Science, Freising-Weihenstephan, Technische Universität München, 80333, Munich, Germany, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158 and Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA 94143, USA.
Harness Julie V
Müller Sabine
Mewes Hans W
Petritsch Claudia
References (26)
26 references, click to expand
  1. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
    Nature. 2013 Jul 11;499(7457):214-218 PMID: 23770567
  2. Patterns of intracranial glioblastoma recurrence after aggressive surgical resection and adjuvant management: retrospective analysis of 43 cases.
    Neurol Med Chir (Tokyo). 2012;52(8):577-86 PMID: 22976141
  3. The role of genetic diversity in cancer.
    J Clin Invest. 2010 Feb;120(2):401-3 PMID: 20101092
  4. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.
    Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97 PMID: 20947487
  5. The clonal evolution of tumor cell populations.
    Science. 1976 Oct 1;194(4260):23-8 PMID: 959840
  6. Tumour evolution inferred by single-cell sequencing.
    Nature. 2011 Apr 7;472(7341):90-4 PMID: 21399628
  7. The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
    Nature. 2012 Apr 04;486(7403):395-9 PMID: 22495314
  8. Robust unmixing of tumor states in array comparative genomic hybridization data.
    Bioinformatics. 2010 Jun 15;26(12):i106-14 PMID: 20529894
  9. The life history of 21 breast cancers.
    Cell. 2012 May 25;149(5):994-1007 PMID: 22608083
  10. A restricted cell population propagates glioblastoma growth after chemotherapy.
    Nature. 2012 Aug 23;488(7412):522-6 PMID: 22854781
  11. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
    Cancer Cell. 2011 Dec 13;20(6):810-7 PMID: 22137795
  12. Brain tumor stem cells: Molecular characteristics and their impact on therapy.
    Mol Aspects Med. 2014 Oct;39:82-101 PMID: 23831316
  13. Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.
    PLoS One. 2011;6(11):e26100 PMID: 22125594
  14. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
    Genes Dev. 2010 Aug 15;24(16):1731-45 PMID: 20713517
  15. Absolute quantification of somatic DNA alterations in human cancer.
    Nat Biotechnol. 2012 May;30(5):413-21 PMID: 22544022
  16. Genetic variegation of clonal architecture and propagating cells in leukaemia.
    Nature. 2011 Jan 20;469(7330):356-61 PMID: 21160474
  17. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma.
    Cancer. 2013 Aug 15;119(16):3034-42 PMID: 23696076
  18. NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy.
    Nucleic Acids Res. 2012 Jan;40(Database issue):D130-5 PMID: 22121212
  19. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells.
    Int J Cancer. 2009 Aug 1;125(3):717-22 PMID: 19431142
  20. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
    Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6 PMID: 22323597
  21. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity.
    Cancer Res. 2012 Apr 1;72(7):1614-20 PMID: 22311673
  22. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Lancet Oncol. 2009 May;10(5):459-66 PMID: 19269895
  23. Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas.
    Cancer Res. 1998 Oct 15;58(20):4694-700 PMID: 9788624
  24. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.
    Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14 PMID: 23412337
  25. Akt and autophagy cooperate to promote survival of drug-resistant glioma.
    Sci Signal. 2010 Nov 09;3(147):ra81 PMID: 21062993
  26. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV.
    Bioinformatics. 2011 Oct 1;27(19):2648-54 PMID: 21828086
Article Info
Journal
Bioinformatics (Oxford, England)
Abbr.
Bioinformatics
ISSN
1367-4811
Published
2014-01-01
Epub
2013-00-30
Pages
50-60
Language
English
Region
England
NLM ID
9808944
PMCID
PMC3866558
Subset
IM
Grants
NCI NIH HHS · T32 CA151022 · United States
NINDS NIH HHS · R01 NS080619 · United States
NINDS NIH HHS · R01NS080619 · United States
NCI NIH HHS · R01 CA164746 · United States
NCI NIH HHS · R01CA164746 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]